SAN FRANCISCO, Feb. 22, 2017 /PRNewswire/ -- Trianni, Inc. (“TRIANNI”) announced today that it has entered into a license agreement with Leland Stanford Junior University (Stanford University) to grant access to The Trianni Mouse, a best-in-class monoclonal antibody discovery platform, in support of vaccine research. The platform will be made available to Stanford through one of TRIANNI’s preferred Contract Research Organization providers.
“Trianni is delighted to partner with Stanford in an important academic alliance,” commented Dr. David Meininger, Trianni’s Chief Business Officer. “We are confident that The Trianni Mouse, with its complete human antibody repertoire and novel chimeric gene segment design, will add tremendous value to Stanford’s cutting-edge vaccine research.”
About Trianni, Inc.
TRIANNI is a privately held organization, formed in 2010 with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company is headquartered in San Francisco, CA. Additional information about TRIANNI is available through its corporate website, www.trianni.com
Contact- Trianni, Inc
David Meininger
Chief Business Officer
1.866.674.9314
david.meininger@trianni.com
Mandy Boyd
Director of Marketing
1.415.231.0256 [o]
1.866.674.9314
mandy.boyd@trianni.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trianni-signs-agreement-with-stanford-university-for-use-of-the-trianni-mouse-in-vaccine-research-300411598.html
SOURCE Trianni, Inc.
